FDA Oncology Announcements

Anti-TACSTD2 ADC × Clear all

5 Announcements

FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer

Trial: TROPiCS-02
Drug: Trodelvy (sacituzumab govitecan-hziy) · Anti-TACSTD2 antibody-drug conjugate
Condition: Breast

FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer

Trial: TROPHY U-01
Drug: sacituzumab govitecan · Anti-TACSTD2 antibody-drug conjugate
Condition: Genitourinary

FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer

Trial: ASCENT
Drug: Trodelvy (sacituzumab govitecan) · Anti-TACSTD2 antibody-drug conjugate
Condition: Breast

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer

Drug: TRODELVY (sacituzumab govitecan-hziy) · Anti-TACSTD2 antibody-drug conjugate
Condition: Breast

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer

Drug: TRODELVY (sacituzumab govitecan-hziy) · Anti-TACSTD2 antibody-drug conjugate
Condition: Breast